08.05.2012 - Satisfied investors again hand out money to UK-biotech Oxford Nanopore. Almost all of the newly raised €39m comes from existing funders.
Oxford – British next generation sequencing specialist Oxford Nanopore Technologies Ltd has announced that its recent fundraising round has been successful. All in all, €39.0m (£31.4m) will lubricate the biotech’s plans to boost its operational standing. CEO Gordon Sanghera wants to spend the money on different fronts: „This round of funding will support a range of corporate development activities including the development of our commercial infrastructure and the expansion of our manufacturing function. We will also continue to maintain our leadership position in nanopore innovation through maintenance and expansion of our broad intellectual property portfolio."
Almost all the money comes from existing investors via private placements of ordinary shares. Oxford Nanopore summed up that the total amount raised in the company’s life since its inception as a University of Oxford spin-off in 2005 is about €130.2m. The up-and-coming high-tech shack has developed a rapid and cheap new sequencing technology based on nanopores to directly and electronically detect and analyse single molecules. Since the first public demonstration of the technology in mid-February friends and foes alike early await its direct to customer commercialisation in the manifestations of the GridION platform and the MinION device in the second half of 2012. Currently, competitors such as Roche/IBM are just in research stage.
20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck.
13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.
09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.
06.01.2015 With the aim to utilise Ireland’s many natural resources and keep abreast of the latest EU developments in bioeconomy, a multi-disciplinary team has been funded to maximise national income, exports and job creation related to Ireland’s bioeconomy.